A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone

Xin Li, Robert Loberg, Jinhui Liao, Chi Ying, Linda A. Snyder, Kenneth J. Pienta, and Laurie K. McCauley

Abstract

Monocyte chemoattractant protein 1 (CCL2) is a recently identified prominent regulator of prostate cancer growth and metastasis. The purpose of this study was to investigate the mechanistic role of CCL2 in prostate cancer growth in bone. The present study found that CCL2 was up-regulated in osteoblasts (3-fold by PC-3 and 2-fold by VCaP conditioned medium) and endothelial cells (2-fold by PC-3 and VCaP conditioned medium). Parathyroid hormone-related protein (PTHrP) treatment of osteoblastic cells up-regulated CCL2 and was blocked by a PTHrP antagonist, suggesting that prostate cancer–derived PTHrP plays an important role in elevation of osteoblast-derived CCL2. CCL2 indirectly increased blood vessel formation in endothelial cells through vascular endothelial growth factor-A, which was up-regulated 2-fold with administration of CCL2 in prostate cancer cells. In vivo, anti-CCL2 treatment suppressed tumor growth in bone. The decreased tumor burden was associated with decreased bone resorption (serum TRAP5b levels were decreased by 50–60% in anti–CCL2-treated animals from VCaP or PC-3 cell osseous lesions) and microvessel density was decreased by 70% in anti–CCL2-treated animals with bone lesions from VCaP cells. These data suggest that a destructive cascade is driven by tumor cell–derived, PTHrP-mediated induction of CCL2, which facilitates tumor growth via enhanced osteoclastic and endothelial cell activity in bone marrow. Taken together, CCL2 mediates the interaction between tumor-derived factors and host-derived chemokines acting in cooperation to promote skeletal metastasis.

Introduction

Monocyte chemoattractant protein-1 (CCL2) is a member of the CC chemokine family and was recently described as facilitating osteoclastogenesis (1, 2). Osteoclastogenesis and bone resorption are independent steps leading to the development of skeletal metastases and are mutually essential for prostate cancer establishment in the bone microenvironment. CCL2 can also directly support prostate carcinoma cell growth in vitro (3, 4). We further showed that targeted inhibition of CCL2 effectively suppressed prostate cancer growth in vivo and suggested that CCL2 may enhance tumor growth through macrophage infiltration and angiogenesis (5). Previous findings suggest that CCL2 can directly mediate angiogenesis in endothelial cells, which express chemokine receptor 2 (CCR2), the receptor for CCL2 (6). Human brain endothelial cells, human umbilical cord vein endothelial cells (HUVEC), and human dermal microvascular endothelial cells (HDMVEC) were reported to express CCR2 and are able to respond to CCL2 by forming more vessel spouts in vitro (6, 7). Conversely, one study showed that HUVECs and HDMVECs do not express CC chemokine receptors (8) and thus are unlikely to be regulated by CCL2. The presence of CCR2 and its angiogenic response to CCL2 may differ in endothelial cells depending on tissue sites. In addition, it is not clear if CCL2 can directly activate endothelial cells in the bone marrow, which would be more relevant to angiogenesis during bone metastasis. Interestingly, human bone marrow endothelial (HBME) cells were found to secrete high levels of CCL2 compared with human aortic endothelial cells (HAEC) and HDMVECs (4), indicating an active role of CCL2 in the bone microenvironment. With recent studies highlighting a role for CCL2 in supporting the development of prostate cancer skeletal metastasis, a better understanding of how CCL2 facilitates tumor growth in bone is important to consider it as a novel therapeutic target for the treatment of bone-specific disease. There seem to be two distinct roles for CCL2 in the development and promotion of prostate cancer: a direct effect on prostate cancer epithelial cells and an indirect effect on cells (i.e., osteoclasts and endothelial cells) at the metastatic site to support tumor growth. Here, we hypothesized that elevated CCL2 in the bone microenvironment contributes to prostate tumor growth by initiating osteoclastogenesis and angiogenesis to create a favorable niche for prostate cancer cells.

Materials and Methods

Materials. Recombinant human parathyroid hormone-related protein (PTHrP) (1-34) and (7-34) were obtained from Bachem. CNT0 888, a human antibody that neutralizes human CCL2, C1142, an anti-mouse CCL2 antibody, and C1322, a control antibody for C1142, were provided by Centocor, Inc. CNT0 888 and C1142 do not cross-react with or neutralize mouse CCL2 or human CCL2, respectively (4). Anti-human IgG from R&D Systems was used as control antibody for CNT0 888. Human rCCL2 was obtained from PeproTech.

Cell culture. All cell lines were from the American Type Culture Collection (ATCC) until otherwise noted. PC-3 and LoCaP were maintained in RPMI 1640 + 10% fetal bovine serum (FBS; Invitrogen). VCaP and HBME cells were obtained from the Rapid Autopsy Program at the University of Michigan (9). HAECs, HBMEs, and VCaP cells were maintained in DMEM containing 10% FBS plus 1% antibiotics (Invitrogen). HDMVECs were maintained in EGM2 (Clonetics) containing 10% FBS and 1% antibiotics.
Human osteoblastic Saos2 cells (ATCC HTB-85) were maintained in MEM (Invitrogen) containing 1% antibiotics and 10% FBS. Saos2 cells were plated at 50,000/cm² and cultured to 80% to 90% confluence. Cells were subsequently treated with vehicle or PTHrP (10 nmol/L) for 4 h after serum starvation. The PTHrP antagonist PTHrP(7-34) (2 μmol/L) was added 30 min ahead of PTHrP treatment as indicated. Primary mouse calvarial cells were isolated as previously described (10). Cells were plated at 80,000 per well in 24-well plates in MEM with 10% FBS containing 1% antibiotics. Primary cultures at 90% confluence were used without passage and treated with PTHrP or vehicle for 4 h.

Protein detection. Bone marrow aspirates, sera, and conditioned media from cell culture were used for protein detection. Bone marrow aspirates were prepared by flushing tibiae or femurs with 1 mL of saline. The number of total cells was counted and used to normalize protein levels. Bone marrow aspirates, sera separated from blood, and conditioned media were aliquoted and kept at −20°C until assays were performed.

Secreted CCL2 protein levels in Saos2, PC-3, endothelial cells, or primary cell culture medium were measured by ELISA assay system from BD Biosciences. Values were calculated from standard curves set up for each assay. Data were based on triplicate experiments performed independently. Serum TRAP5b activity was measured by ELISA (Immuno-diagnostics Systems, Inc.) following the manufacturer's instructions. Vascular endothelial growth factor-A (VEGF-A) levels in the conditioned medium of PC-3 cells were measured using an ELISA assay from R&D Systems.

In vivo prostate cancer models. Five-week-old CB17 severe combined immunodeficient mice obtained from Charles River Laboratories were used for s.c. and intratibial tumor implantation. VCaP and PC-3 cells were cultured in T-75 flasks to 100% confluence, trypsinized, and enumerated. Mice were sedated with 1.7% isoflurane mixed with air for s.c. and intratibial tumor implantation. Xenograft tumors were established by s.c. injection of 10⁶ VCaP or PC-3 prostate cancer cells in 200 μL of growth factor–reduced Matrigel (BD Biosciences) as previously described (11). Animals were sacrificed after 4 wk. There were no significant body weight differences in the animals with or without s.c. tumors at the time of sacrifice. For intratibial tumor injection, a 27-gauge needle was used to bore a hole in the marrow cavity through the tibial plateau into the left tibia as described previously (5). A 28-gauge Hamilton syringe was used to inject 5 × 10⁵ cells in a 10 μL volume into the marrow cavity. Animals were sacrificed after 8 wk. Tibias were removed, placed in 10%

![Figure 1](cancerres.aacrjournals.org)
formaldehyde for 24 h, and then transferred to 70% ethanol. All animal studies were approved by the University of Michigan Committee on the Use and Care of Animals.

Treatment with anti-CCL2 (C1142). Before intratibial injection, mice were pretreated with 2 mg/kg anti-mouse CCL2 (C1142). Control mice were treated with either 2 mg/kg isotype control antibody (C1322) or PBS. Following intratibial injection with PC-3 or VCaP prostate cancer cells as described above, mice continued treatment twice weekly until the end of the experiment.

Histology and immunohistochemistry. Xenograft tumors were harvested and placed in fresh 10% formalin. Tibiae were decalcified in 10% EDTA before paraffin embedding. Specimens were sectioned (5 μm) and stained with either H&E, trichrome (to highlight bone), tartrate-resistant acid phosphatase (TRAP; to identify osteoclasts; Acid Phosphatase Leukocyte kit, Sigma), or immunohistochemistry performed for von Willebrand factor (vWF; NeoMarkers). Standard indirect immunoperoxidase procedures were used for immunohistochemistry using the AEC Cell and Tissue staining system (R&D Systems), with Mayer’s hematoxylin (Sigma) used for counterstaining.

For microvessel density (MVD) analysis, after vWF staining, four random areas per tumor section were selected. Any single or cluster of positively stained endothelial cells that was clearly separated from adjacent microvessels was considered as one countable microvessel. The average MVD was determined for each specimen.

Endothelial sprout network formation assay. Growth factor–reduced Matrigel was placed in eight-well chamber slides and polymerized at 37°C for 30 min. Eight thousand (8 × 10^4) endothelial cells were added to the top of the Matrigel in each well. After 24-h incubation at 37°C, the slides were fixed, stained with Hema3 STAT PACK (Protocol), and analyzed by enumerating the sprouts under a light microscope.

Quantitative PCR assay. Total RNA was isolated from cultured cells using Tri reagent (Sigma) and 1 μg total RNA was reverse transcribed in a 20 μL reaction volume containing random hexamers with a reverse transcription assay system (Applied Biosystems). Quantitative reverse transcription-PCR (RT-PCR) was performed using the ABI PRISM 7700 with a ready-to-use mix of primers and FAM-labeled probe assay system (Applied Biosystems). Data were calculated using the standard curve method and expressed as a ratio to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reference.

Statistical analysis. Student’s t test for independent analysis was applied to evaluate differences using the GraphPad InStat software program (GraphPad Software, Inc.). The value P < 0.05 was considered statistically significant. In vitro assays were repeated a minimum of two times with similar results. For in vivo assays, n indicates the number of independent samples from different mice.

Results

Prostate tumors elevate CCL2 expression in bone marrow, osteoblasts, and endothelial cells. To determine the ability of a primary tumor to alter the bone microenvironment as a premetastatic event, PC-3 and VCaP cell xenografts were implanted s.c. and allowed to develop for 4 weeks. At 4 weeks, bone marrow aspirates were collected from the tibiae and analyzed for CCL2 expression. The presence of PC-3 and VCaP cell xenografts significantly increased the levels of CCL2 ~2-fold in the bone marrow compared with control animals (Fig. 1A). In separate experiments, s.c. injection of PTHrP also significantly up-regulated CCL2 in the bone marrow (Fig. 1B) and serum (Supplementary Fig. S1), which is consistent with the hypothesis that PTHrP, secreted from primary tumors, mediates up-regulation of CCL2 in the bone marrow. Previously, we showed that CCL2 is expressed at high levels by bone marrow endothelial cells (4). Here, we measured the CCL2 levels in vitro when endothelial cells were cultured with prostate cancer cell conditioned medium. The conditioned medium from prostate cancer cell lines (PC-3, VCaP,

![Figure 2](https://example.com/figure2.png)

**Figure 2.** PTHrP increases CCL2 in osteoblasts but not endothelial cells. Saos2 cells (A) were plated at 50,000/cm² and endothelial cells (C and D) were plated at 30,000/cm², grown to 80% to 90% confluence, and subsequently treated with vehicle or PTHrP(1-34) at 10 nmol/L for 4 h after serum starvation. PTHrP antagonist, PTHrP(7-34) (2 μmol/L), was added 30 min before PTHrP(1-34) treatment. Primary mouse osteoblasts (B) were treated with PTHrP or vehicle for 4 h without serum starvation. CCL2 levels in the medium were measured by ELISA. Columns, mean (n = 3); bars, SE. **, P < 0.01 versus vehicle control; *, P < 0.05 versus PTHrP-treated group.
or LnCaP) increased the levels of CCL2 produced by endothelial cells [bone marrow endothelial cells (HBME), aortic endothelial cells (HAEC), and dermal microvascular endothelial cells (HDMVEC); Fig. 1C; Supplementary Fig. S2]. A significant increase of CCL2 was also found in human osteoblastic (Saos2) cells cultured with conditioned medium from prostate cancer cell lines PC-3 (3-fold) and VCaP (2-fold), both of which secrete high levels of PTHrP. Conditioned medium from the low PTHrP-secreting prostate cancer cell line, LnCaP, failed to stimulate CCL2 secretion from Saos2 cells (Fig. 1D). Further, stimulation of primary osteoblasts and Saos2 cells but not endothelial cells (HAEC and HBME) with PTHrP (10 nmol/L) increased secretion of CCL2 by 2.5-fold (Fig. 2). To confirm that the increase in CCL2 was due to PTHrP, PTHrP(7-34) was used as an antagonist to suppress PTHrP signaling. PTHrP(7-34) competes with PTHrP for binding to its receptor but does not activate cyclic AMP and hence blocks signaling (12). PTHrP(7-34) suppressed the PTHrP-induced CCL2 increase in osteoblasts, whereas it had no effect on endothelial cells. This suggests that tumor cell–derived PTHrP increases CCL2 production by osteoblasts.

**Antibody to CCL2 reduces tumor burden and MVD.** To determine the role of CCL2 in prostate cancer metastatic bone establishment and growth, systemic inhibition of CCL2 was accomplished using a neutralizing antibody that targets mouse CCL2 (C1142). Mice were inoculated with either PC-3 or VCaP prostate cancer cells. VCaP cells were originally isolated from a vertebral metastatic lesion obtained via the University of Michigan Rapid Autopsy Program (9). PC-3 cells are osteolytic, androgen receptor negative, and androgen independent, whereas VCaP cells express a wild-type androgen receptor and are androgen sensitive. Both PC-3 and VCaP cells are known to express the CCL2 receptor CCR2 (4). Mice were injected with PC-3 or VCaP cells by intratibial injection and bone lesions were monitored weekly using radiographic imaging. PC-3 cells established visible osteolytic lesions by

---

**Figure 3.** CCL2 antibody treatment decreased tumor burden and bone resorption. Representative images of tibial sections from mice with intratibial injection of VCaP (A) or PC-3 tumor cells (B) with H&E staining, Masson’s trichrome staining, and TRAP staining as indicated. C and D, serum TRAP5b levels in mice treated with anti-mouse CCL2 antibody (C1142) or control antibody (C1322). *, P < 0.001 versus C1322. Columns, mean (n = 4); bars, SE.
week 6 and VCaP cells established a mixed osteolytic/osteoblastic lesion by week 10.

Tibias were harvested and examined via immunohistochemical analysis (Fig. 3). Overall tumor burden was significantly decreased in tibias of mice receiving C1142 (anti-mouse CCL2) antibody compared with control antibody (C1322). Bone destruction was decreased, as observed by trichrome staining for mineralized bone matrix, in animals receiving C1142 (VCaP: Fig. 3A). Additionally, inhibition of CCL2 attenuated TRAP-positive osteoclast staining, suggesting an inhibition of osteoclast activity (VCaP: Fig. 3A; PC-3: Fig. 3B). Interestingly, mice inoculated with VCaP cells failed to develop obvious osteolytic lesions when treated with the anti-CCL2 antibody. Analysis of serum markers of osteoclast activity revealed a significant decrease in TRAP5b serum levels in animals receiving anti-mouse CCL2 antibody compared with controls (Fig. 3C and D). Immunostaining for vWF in tibial sections of mice that had received intratibial injections of VCaP tumor cells revealed decreased MVD in animals receiving anti-mouse CCL2 antibody compared with controls (Fig. 4).

Proangiogenic effect of CCL2. It has been reported that some human endothelial cells express the receptor for CCL2 (CCR2) and respond to CCL2 (6), but it is not clear whether HBMEs respond to CCL2. This is particularly relevant because bone marrow endothelial cells are the most abundant endothelial cell type in skeletal lesions. Our study showed that CCL2 stimulated tumor cells to produce a proangiogenic factor(s) instead of directly stimulating bone marrow endothelial cells (Fig. 5). Conditioned medium from CCL2-treated PC-3 cells significantly increased sprout formation in HBMEs, whereas pretreating PC-3 cells with anti-CCL2 antibody abolished this effect (Fig. 5A and B). CCL2 itself failed to stimulate capillary tube formation of HBMEs when added directly (Supplementary Fig. S3). CNTO 888 alone, the antibody to human CCL2, had no effect on capillary tube formation. CCL2 increased VEGF-A mRNA levels from PC-3 cells after 4 and 6 hours (Fig. 5C). The stimulation of VEGF-A mRNA in PC-3 cells was specifically mediated by CCL2 because it could be blocked with pretreatment of the neutralizing antibody to the tumor cells. The increase of VEGF-A protein in CCL2-stimulated PC-3 cells was confirmed by ELISA (Fig. 5D), resulting in a 60% increase of VEGF-A after serum-starved PC-3 cells were incubated with CCL2 for 24 hours.

Taken together, our model proposes an explanation of how CCL2 facilitates prostate cancer growth in bone (Fig. 6). PTHrP released from prostate cancer stimulates osteoblastic CCL2 expression (Figs. 1 and 2), which causes increased osteoclastic bone resorption (Fig. 3; refs. 1, 2), and in turn facilitates prostate cancer tumor localization in bone (4, 5). Meanwhile, CCL2 binds to its receptor on prostate cancer cells and stimulates tumor cells to release the proangiogenic factor VEGF-A (Fig. 5). VEGF-A enhances the formation of blood vessels to support further tumor growth (Figs. 4 and 5). Thus, CCL2 plays a key role in the destructive cascade, which favors tumor growth via activation of tumor cells, bone resorption, and angiogenesis.

Discussion

Prostate cancer characteristically forms osteoblastic lesions when it metastasizes to bone. It is becoming clear that osteoclast activation is an essential component of prostate cancer skeletal metastases, although the mechanism, timing, and relationship to the osteoblastic component remain unclear. Growth factors and calcium released from the bone matrix during resorption subsequently support tumor growth in bone. Here, we present data that show the importance of the chemokine CCL2 in developing prostate cancer metastatic bone lesions using a s.c. and an intratibial model of prostate cancer. S.c. tumor implantation induced elevation of CCL2 in the bone marrow compartment before tumor metastasis in vivo. CCL2 is released from osteoblasts and bone marrow endothelial cells endogenously and is further induced by tumor cell–derived factors. In osteoblasts, CCL2 was stimulated in response to PTHrP. Metastatic prostate carcinoma in bone secretes high levels of PTHrP that are important in the establishment of prostate cancer in the bone microenvironment (13–16). Tumor-derived PTHrP is known to up-regulate receptor activator of nuclear factor-κB ligand, an essential factor in

![Figure 4](image_url) Blocking CCL2 decreased MVD in intratibial VCaP bone lesions. Representative images of vWF staining in tibia of mouse treated with control antibody (C1322; A) or anti-mouse CCL2 antibody (C1142; B) after intratibial inoculation of VCaP cells. C, total number of blood vessels was counted per section of tibia with bone lesions. *, P < 0.01. Columns, mean (n = 4); bars, SE.

The figure shows the effect of blocking CCL2 on MVD in intratibial VCaP bone lesions. The figure includes A, B, and C images.
osteoclastogenesis. Furthermore, CCL2 has been shown to directly stimulate the proliferation of prostate cancer cells and favors osteoclastogenesis by facilitating the fusion of osteoclast precursor cells (1–4). It has been shown that PTH regulates CCL2 expression in bone through osteoblasts (2). PTHrP, which acts on the same receptor (PTHR1) as parathyroid hormone, was found here to regulate osteoblastic expression of CCL2. The stimulation of CCL2 by PTHrP in osteoblasts and the high level of CCL2 secreted by bone marrow endothelial cells could activate osteoclasts and enhance bone resorption to favor tumor cell localization.

It was reported that CCL2 released from endothelial cells and osteoblasts mediates prostate cancer–induced bone resorption (17). An in vitro system used in that study showed that PC-3 prostate cancer cell conditioned medium induced bone resorption in human bone marrow mononuclear cells, and bone resorption was inhibited with CCL2 neutralizing antibodies. The present study applied in vivo experiments that targeted CCL2 with a neutralizing antibody and elucidated mechanisms for the CCL2 effect on tumorigenesis. Significantly decreased bone resorption and tumor burden were found with CCL2 neutralizing antibody treatments. PC-3 cells are known to form highly lytic lesions compared with VCaP cells that form a mixture of osteolytic and osteoblastic lesions. It is interesting that the anti-CCL2 neutralizing antibody partially reduced PC-3 tumor growth and TRAP-positive osteoclast activity and almost completely inhibited osteoclast activation and establishment of VCaP tumors. This may suggest that osteolysis is an important early event in the establishment of prostate cancer in the bone compartment. The purely lytic PC-3 cells may retain the ability to establish bone lesions with anti-CCL2 challenge, whereas anti-CCL2 completely inhibited the ability of VCaP cells to establish bone tumors. The decreased tumor growth was accompanied by a decrease in TRAP5b serum levels, supporting the inhibition of osteoclast activity by inhibiting CCL2.

In addition, systemic inhibition of CCL2 with a neutralizing antibody was found to inhibit the growth and establishment of prostate cancer cells in the bone microenvironment in association with suppression of angiogenesis. Whether CCL2 directly stimulates angiogenesis in endothelial cells is controversial (6, 18–21). Different tissue-derived endothelial cells may respond distinctively to CCL2. It has been reported that HUVECs and HDMVECs do not express receptors for CCL2 nor do they respond to CCL2 (8). However, another study reported that HUVECs express receptors for CCL2 and respond to CCL2 (6). We tested several endothelial cells, including HBMEs, HAECs, and HDMVECs, and did not find CCR2, the primary receptor for CCL2 (data not shown), nor did they respond to CCL2. So it is unlikely that CCL2 exerts direct endotheliotropic effects in these cells. Furthermore, we did not see any effect of CCL2 alone on angiogenesis in HBMEs. However, the absence of evidence to support direct effects of CCL2 on endothelial cells does not diminish the important role of CCL2 in angiogenesis during tumor growth. CCL2 was found to stimulate the expression of VEGF-A in tumor cells in vitro and conditioned medium.
medium from tumor cells treated with CCL2 potently induced angiogenesis of HBMEs. The stimulation of VEGF-A expression by CCL2 has been reported in several cell types, including endothelial cells (22) and vascular smooth muscle cells (23). Animals with intratibial tumor cell inoculation and treated with neutralizing antibody for CCL2 had decreased blood vessel density in bone lesions. Consistent with these findings, the correlation of CCL2 expression with MVD and tumor invasion has been shown in breast carcinomas (24), head and neck squamous cell carcinoma (25), and gastric carcinomas (26).

Besides stimulating VEGF-A release from tumor cells to facilitate angiogenesis, CCL2 may act as an indirect inflammation-associated inducer of angiogenesis through activation of macrophage infiltration (5, 26–30). In addition, CCL2 could stimulate angiogenesis through enhanced osteoclastogenesis, which results in release of bone matrix-bound angiogenic factors, such as platelet-derived growth factor, fibroblast growth factor (FGF)-1, FGF-2, and transforming growth factor-β (31). Both mechanisms could contribute to the neo-blood vessel formation during the development of bone lesions from prostate carcinomas. Taken together with the fact that CCL2 can also contribute to tumor progression through direct activation of cell adhesion and motility in prostate cancer cells (32), targeting CCL2 provides a promising therapeutic strategy for prostate cancer skeletal metastasis.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

Received 6/6/2008; revised 11/25/2008; accepted 11/26/2008; published OnlineFirst 01/27/2009.

Grant support: National Cancer Institute award P01-CA093900.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Amy Koh for critical reading of the manuscript and Chris Strayhorn (University of Michigan, School of Dentistry Histology Core Facility) for technical assistance in processing histologic sections.

**References**

10. Chen HI, Demiralp B, Schneider A, et al. Parathyroid...
hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 2002;277:19374–81.


A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone

Xin Li, Robert Loberg, Jinhui Liao, et al.